Brief: Resverlogix commences phase 3 clinical trial BETonMACE with Apabetalone
26/10/2015 11:00
Oct 26 (Reuters) - Resverlogix Corp RVX.TO : * Commences phase 3 clinical trial BETonMACE with Apabetalone * Apabetalone will be evaluated in a phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients * Source text for Eikon ID:nPnplZ3b * Further company coverage RVX.TO ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment